A securities class action has been filed against VistaGen and certain officers on behalf of investors who purchased or acquired its securities between April 1, 2024 and December 16, 2025. The complaint alleges the defendants made materially false or misleading statements about the development and prospects of fasedienol, an investigational treatment for social anxiety disorder. It also alleges the company disseminated false or misleading information or concealed material adverse data regarding the design, execution, and results of the Phase 3 PALISADE-3 trial. More information is posted at bgandg.com/VTGN.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603121200PRIMZONEFULLFEED9668484) on March 12, 2026, and is solely responsible for the information contained therein.